S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL

Antzeko izenburuak

• Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
  nork: Carsten U. Niemann, et al.
  Argitaratua: (2025-08-01)
• S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
  nork: Aleksandra Urban, et al.
  Argitaratua: (2023-08-01)
• Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
  nork: Thomas E. Lew, et al.
  Argitaratua: (2020-01-01)
• Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
  nork: Carsten Utoft Niemann, et al.
  Argitaratua: (2020-10-01)
• P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
  nork: Sabina Kersting, et al.
  Argitaratua: (2023-08-01)